An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors

ConclusionsCoadministration of lenvatinib had no clinically relevant effect on the pharmacokinetics of midazolam, a CYP3A4 substrate. The adverse events were consistent with the known safety profile of lenvatinib, and no new safety concerns were identified.ClinicalTrials.Gov IdentifierNCT02686164.

http://link.springer.com/10.1007/s13318-020-00607-7

Source: European Journal of Drug Metabolism and Pharmacokinetics - February 17, 2020 Category: Drugs & Pharmacology Source Type: research